Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

被引：75

作者：

Tabernero, Josep

Van Cutsem, Eric

Bang, Yung-Jue

Fuchs, Charles S.

Wyrwicz, Lucjan

Lee, Keun Wook

Kudaba, Iveta

Garrido, Marcelo

Chung, Hyun Cheol

Salguero, Hugo Raul Castro

Mansoor, Wasat

Braghiroli, Maria Ignez Freitas Melro

Goekkurt, Eray

Chao, Joseph

Wainberg, Zev A.

Kher, Uma

Shah, Sukrut

Kang, SoonMo Peter

Shitara, Kohei

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Inst Oncol, Barcelona, Spain

[3] Univ Hosp Gasthuisberg, Leuven, Belgium

[4] Katholieke Univ Leuven, Leuven, Belgium

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Yale Canc Ctr, New Haven, CT USA

[7] M Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[8] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[9] Riga East Univ Hosp, Riga, Latvia

[10] Pontificia Univ Catolica Chile, Santiago, Chile

[11] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[12] Hosp Enfermedad Comun Igss Zona 9, Guatemala City, Guatemala

[13] Christie NHS, Manchester, Lancs, England

[14] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[15] Univ Canc Ctr Hamburg, Hamburg, Germany

[16] City Hope Comprehens Canc Ctr, Duarte, CA USA

[17] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] Merck & Co Inc, Rahway, NJ 07065 USA

[20] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 18期

关键词：

D O I：

10.1200/JCO.2019.37.18_suppl.LBA4007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4007

引用

页数：2

共 50 条

[21] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
Janjigian, Yelena Y.
Kawazoe, Akihito
Yanez, Patricio Eduardo
Luo, Suxia
Lonardi, Sara
Kolesnik, Oleksii
Barajas, Olga
Bai, Yuxian
Shen, Lin
Tang, Yong
Wyrwicz, Lucjan
Shitara, Kohei
Qin, Shukui
Van Cutsem, Eric
Tabernero, Josep
Li, Lie
Shih, Chie-Schin
Bhagia, Pooja
Chung, Hyun Cheol Cheol
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Association of Tumor Mutational Burden with Efficacy of Pembrolizumab plus Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Lee, Keun-Wook
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles S.
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Lee, Jeeyun
Castro, Hugo R.
Chao, Joseph
Wainberg, Zev A.
Cao, Z. Alexander
Aurora-Garg, Deepti
Kobie, Julie
Cristescu, Razvan
Bhagia, Pooja
Shah, Sukrut
Tabernero, Josep
Shitara, Kohei
Wyrwicz, Lucjan
CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3489 - 3498
[23] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Shitara, Kohei
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles
Wyrwicz, Lucjan
Lee, Keun-Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Lee, Jeeyun
Castro, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Caglevic, Christian
Villanueva, Luis
Goekkurt, Eray
Satake, Hironaga
Enzinger, Peter
Alsina, Maria
Benson, Al
Chao, Joseph
Ko, Andrew H.
Wainberg, Zev A.
Kher, Uma
Shah, Sukrut
Kang, S. Peter
Tabernero, Josep
JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580
[24] Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
Fuchs, Charles S.
Denker, Andrew E.
Tabernero, Josep
Van Cutsem, Eric
Ohtsu, Atsushi
Lam, Baohoang
Koshiji, Minori
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[25] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Qin, S.
Tabernero, J.
van Cutsem, E.
Fuchs, C. S.
Janjigian, Y. Y.
Bhagia, P.
Li, K.
Adelberg, D.
Bang, Y-J.
ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
[26] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Rha, S. Y.
Wyrwicz, L. S.
Weber, P. E. Y.
Bai, Y.
Ryu, M. H.
Lee, J.
Rivera, F.
Alves, G. V.
Garrido, M.
Shiu, K. -k.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F. J. S. M.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Oh, D-y.
ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
[27] Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
Shitara, K.
Rha, S. Y.
Wyrwicz, L. S.
Oshima, T.
Karaseva, N.
Osipov, M.
Yasui, H.
Yabusaki, H.
Afanasyev, S.
Park, YK.
Al-Batran, SE.
Yoshikawa, T.
Weber, P. E. Yanez
Di Bartolomeo, M.
Lonardi, S.
Fang, X.
Shih, CS.
Bhagia, P.
Bang, YJ.
ANNALS OF ONCOLOGY, 2023, 34 : S1316 - S1316
[28] Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer.
Yin, Xianli
Zhang, Yun
Deng, Yanhong
Xu, Nong
Xu, Jianming
Li, Lei
Song, Xiaotong
Lu, Haolan
Gong, John
Liu, Dongfang
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] KEYNOTE-585: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles
Ohtsu, Atsushi
Tabernero, Josep
Ilson, David
Hyung, Woo Jin
Strong, Vivian
Goetze, Thorsten
Yoshikawa, Takaki
Tang, Laura
Sun, Linda
Hasan, Aisha
Koshiji, Minori
Shitara, Kohei
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[30] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
Shitara, K.
Ozguroglu, M.
Bang, Y. J.
Di Bartolomeo, M.
Mandala, M.
Ryu, M. H.
Fornaro, L.
Olesinski, T.
Caglevic, C.
Chung, H.
Muro, K.
Gokkurt, E.
Mansoor, W.
McDermott, R.
Schacham-Shmueli, E.
Chen, X.
Kang, S. P.
Mayo, C.
Ohtsu, A.
Fuchs, C.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →